Until recently, the only strategy to develop drugs regulating GPCR activity was through the identification of compounds that directly acted on the orthosteric sites for endogenous ligands. However, many efforts have recently been made in order to identify small molecules that are able to interact with allosteric sites. These sites are less well-conserved; therefore, allosteric ligands have greater selectivity on the specific receptor. Strikingly, the use of allosteric modulators can provide specific advantages, such as an increased selectivity for GPCR subunits and the ability to introduce specific beneficial therapeutic effects without disrupting the integrity of complex physiologicallyregulated networks. In 2010, our group unexpectedly found that SB269652, a compound supposed to interact with the orthosteric binding site of dopamine receptors, was actually a negative allosteric modulator of D 2 and D 3 receptor dimers, thus identifying the first allosteric small molecule acting on these important therapeutic targets. This review addresses the progresses in the understanding of the molecular mechanisms of interaction between the negative modulator SB269652 and D 2 and D 3 dopamine receptor monomers and dimers, and also the perspectives of developing new dopamine receptor allosteric drugs based on SB269652 as the leading compound.
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Introduction
After more than half a century, dopamine receptors still remain the main target of antipsychotic drugs.
The first-generation antipsychotics began in 1952 with the serendipitous discovery that the antihistamine chlorpromazine reversed the symptoms of a severely agitated psychotic male in the military hospital in Paris (Hamon et al., 1952) . This was the start of the neuropharmacological revolution (Ban, 2007) .
At a later time, second-generation antipsychotics called atypical were introduced in clinical use with a better pharmacological profile, particularly in terms of motor extrapyramidal side effects (Meltzer and Massey, 2011) . In addition, they seem to have additional therapeutic properties such as cognitive enhancement and an improvement in the negative symptoms of schizophrenia. In general, the mechanism of action of first-generation antipsychotics is to block dopamine D 2 receptors, while other explanations have been proposed besides D 2 receptors for second generation antipsychotics, mostly involving 5-HT 1a and 5-HT 2a serotonin receptors, as well as muscarinic, adrenergic, glutamatergic and histamine receptors (Meltzer and Massey, 2011) . Among the second-generation antipsychotics, clozapine is considered the "gold standard" for treating schizophrenia (Meltzer, 2012) .
In this class of second generation antipsychotics, aripiprazole distinguishes itself from the others with a particular mechanism of action, such as being a partial agonist at D 2 receptor (Keck and McElroy, 2003) . However, some authors have questioned this mechanism and have proposed that aripiprazole is a functionally selective antagonist for the D 2 /β-arrestin2 interaction and a partial agonist for D 2 -induced G-protein activation (Mailman and Murthy, 2010) . In addition, interactions with 5-HT 1a and 5-HT 2a receptors may contribute to its antipsychotic activity (Stark et al., 2007) . The synthesis of these two generations of antipsychotic drugs was based on targeting the orthosteric site of dopamine and other GPCRs.
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Dopamine receptors belong to the monoaminergic G protein-coupled receptors (GPCRs) family and represent an important pharmacological target for the treatment of schizophrenia and Parkinson's disease (Missale et al., 1998) The dopamine receptor orthosteric site is located deep in the core structure of these receptors. In particular, dopamine binds, with its protonated amino group, to an aspartic acid in the transmembrane region III and with its catechol moiety to serine residues in the transmembrane region V. On this matter, GPCR crystallization has become a crucial step to understanding in detail the structure and dynamics of receptor binding and functioning. Consistent with this notion, the increased number of GPCR crystal structures resolved in recent years has allowed the characterization of mechanisms of receptor activation and led the way to the synthesis of more selective and potent drugs. For example, the recent crystallization of the dopamine D 3 receptor (Chien et al., 2010) , which has 76% homology with the dopamine D 2 receptor, has opened the way to the structure-guided development of new dopamine receptor drugs (Keck et al., 2014) , and to the characterization of antipsychotic inhibition mechanisms (Salmas et al., 2016) .
Amongst the various mechanisms that could explain receptor versatility, homo-and heterodimerization have received general recognition as being responsible for tuning, diversifying and amplifying GPCR signaling, which strongly suggests that very complex interactions take place between ligands and receptor quaternary structures (Maggio et al., 2007; Ferre et al., 2014) . Indeed, it has been shown that agonists or antagonists bind to one protomer of a GPCR dimer, altering binding and the functional properties of agonists, or antagonists interacting with the other protomer, which suggests an allosteric type of interaction between the two protomers (Carrillo et al., 2003 (Scarselli et al., 2001; Lee et al., 2004; Fiorentini et al., 2008; Aloisi et al., 2011; Pou et al., 2012) .
As a matter of fact, another way to target GPCRs is to use allosteric modulators, which are compounds interacting with binding sites that are topographically distinct from the orthosteric site recognized by the receptor's endogenous agonist and have not evolved to accommodate endogenous ligands (May et al., 2007; Rossi et al., 2009 ). The use of allosteric modulators has specific advantages, such as the increased selectivity for GPCR subunits and the ability to introduce specific beneficial therapeutic effects without disrupting the integrity of complex physiologically-regulated networks. In particular, this review summarizes a new mechanism of allosteric regulation across dopamine receptor dimers and the development of new allosteric drugs for dopamine receptors.
SB269652 is an atypical allosteric modulator for D 2 and D 3 dopamine receptors
Recently, our group has discovered the first negative allosteric modulator for D 2 and D 3 dopamine receptors, the N-((trans)-4-(2-(7cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) (Figure 1) (Silvano et al., 2010) . This compound was originally synthesized by SmithKline Beecham Pharmaceuticals in an effort to find new selective dopamine D 3 antagonists binding to the orthosteric site of the receptor (Reavill et al., 2000; Stemp et al., 2000) . Our group re-evaluated this compound in an effort to find ligands that are able to distinguish between D 2 and D 3 homo-and hetero-receptors. During this re-evaluation, SB269652 was confirmed to have a higher affinity for D 3 compared to D 2 receptors, but importantly, a few SB269652 properties were also identified that eventually led us to the conclusion that this compound was an atypical, negative, allosteric modulator for D 2 and D 3 receptors (Silvano et al., 2010) . In particular, in binding assays with Chinese hamster ovary (CHO) transfected cells, SB269652 potently abolished the specific binding of This article has not been copyedited and formatted. The final version may differ from this version. and phosphorylation of ERK1/2 and Akt at high concentrations of dopamine (Silvano et al., 2010) .
The allosteric nature of this compound was also shown by using chimeric D 2 /D 3 receptors in which their second extracellular loops were switched between the two dopamine receptors (Silvano et al., 2010) . This loop has a pivotal role in binding SB269652 with high affinity, and crystallographic analysis has shown that, together with extracellular loop I and the junction of transmembrane helices I, II, and VII, loop II delimits an allosteric site which may interact with bitopic or pure allosteric ligands (Chien et al., 2010 (Lane et al., 2014) . In particular, they showed that SB269652 was a bitopic compound. Bitopic molecules are typically composed of two pharmacophores bridged by a spacer and characterized by the ability to simultaneously bind to the orthosteric and allosteric sites of the same protomer. The bitopic nature of SB269652 was revealed by fragmenting it. In particular, they generated progressively truncated fragments of the 7-cyano-tetrahydroisoquinoline (7CN-THIQ) moiety of SB269652 that contains the tertiary amine, the part of the molecule that is important for the interaction with the conserved aspartic acid of the amine receptors in the orthosteric site. Contrary to SB269652 whole, all 7CN-THIQ fragments were always able to inhibit dopamine action, in a competitive manner, regardless of its concentration, whereas the other active component of SB269652, the indole-2-carboxamide fragment, inhibited dopamine action in a non-competitive manner. The
properties of these fragments were tested in functional and radioligand binding experiments (Lane et al., 2014) .
Nevertheless, bitopic ligands should not show allosteric properties because they bind to the orthosteric and allosteric sites simultaneously. In fact, allosteric interactions should change the orthosteric binding pocked environment and consequently affect the ability of orthosteric ligands to bind the orthosteric site of the receptor. For instance, extended-length 4-phenylpiperazine derivatives are known to dock to the orthosteric site with the 4-phenylpiperazine moiety and to an allosteric site with the extended aryl amide moiety, but their interaction at the secondary site does not allosterically modulate their binding to the orthosteric site (Furman et al., 2015) . Lane et al. (2014) further extended the description of the mechanism of SB269652 binding, providing that the allosteric action of SB269652 was exerted across dopamine receptor dimers, as depicted in Figure 1 . Reassuming, SB269652 binds in a bitopic mode to one protomer of a dopamine receptor dimer, the 7CN-THIQ part binds to the orthosteric site and the concentrations of radioligands or dopamine increase, more dimers will be occupied and the allosteric effect of SB269652 will be more evident. Furthermore, as discussed below, agonists promote dopamine receptor dimer formation (Tabor et al., 2016) , which might help to unveil the allosteric effects of SB269652 in the functional assays with dopamine.
SB269652 influence on the radioligand dissociation constant reveals additional complexity
Negative and positive allosteric compounds alter ligand association and/or dissociation kinetics (Conn et al., 2009; Maggio et al., 2013) . The affinity of a compound for its target is related to its association and dissociation rate constants that is quantified by K D = K off /K on , where K D represents the equilibrium dissociation constant and K off and K on represent the dissociation and association rate constants, respectively. Consistent with this notion, when an allosteric compound modifies the affinity of a ligand for the orthosteric site, its dissociation and association rate constants must change accordingly. Usually, negative allosteric compounds increase the dissociation rate constant and/or decrease the association rate constant. Strikingly, Silvano et al. (2010) demonstrated that SB269652 does not behave as a common negative allosteric modulation, in fact it largely reduces both radioligand association and dissociation rate constants for D 2 and D 3 receptors (Silvano et al., 2010) . A similar effect has been described for the antagonist methoctramine at muscarinic M 2 receptors (Jakubík et al., 2014) .
Methoctramine is a bitopic compound that competes with orthosteric ligands by simultaneously binding
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. Even though counterintuitive, an alternative explanation is that SB269652 could reduce the dissociation rate constant of the radioligand only across receptor dimers. Nevertheless, this seems unlikely as a biphasic dissociation curve of the radioligands should have been seen inasmuch as only a fraction of the dopamine receptors is in the dimeric form (Tabor et al., 2016) . Then the most parsimonious explanation is that SB269652 binds with high affinity in a bitopic mode to unoccupied receptors and exerts a predominant allosteric effect across dimers; furthermore, it could bind with low affinity solely at the allosteric site(s) of occupied receptors reducing ligand dissociation (Figure 1) . Clearly the ability of SB269652 to bind multiple allosteric sites depending on the D 2 and D 3 receptor occupancy status requires further investigations.
SB269652 as the leading compound that led to the development of new antipsychotic drugs
In order to develop new effective antipsychotic drugs, SB269652 could be exploited in two different ways: 1) to maintain its bitopic effect and improve its affinity and allosteric effect across dimers at D 2 receptors, or 2) to design pure and more potent allosteric drugs starting from its indole-2-carboxamide moiety.
By pursuing the first strategy, Shonberg et al. (2015) synthesized a series of compounds that bind to dopamine D 2 receptors in a bitopic manner but with higher affinity compared to the original ligand SB269652. To this purpose, they focused on modifying the three main parts of SB269652: the 7CN-THIQ, the indole-2-carboxamide moieties and the trans-cyclohexylene linker. They found that the orthosteric "head" groups with small 7CN-THIQ substituents were important to maintain the negative cooperativity of SB269652. Among several substitutions, the hydrogen substitution of the nitrile group The second approach in order to generate analogues with an improved "allosterism" was to break down SB269652 into small molecules containing the indole-2-carboxamide group .
Strikingly, Mistry et al. (2015) showed that, in a series of binding and functional assays, the 1H-indole-2-carboxamide moiety (compound 3 in Mistry et al., 2015 , Figure 2 ) behaved as a pure allosteric drug for D 2 receptors, even though its affinity and negative cooperativity were weaker than SB269652 . Furthermore, Mistry et al. (2015) showed that this molecule had similar affinity and negative allosteric effects for D 3 dopamine receptors compared to the D 2 receptors, which strongly suggested that the difference in SB269652 affinity for D 2 and D 3 receptors was due to the binding of This article has not been copyedited and formatted. The final version may differ from this version. 14 the 7CN-THIQ moiety to the orthosteric site of the two receptors (Silvano et al., 2010) . Interestingly, Mistry et al. (2015) also found that the 1H-indole-2-carboxamide moiety, in ERK1/2 functional assays reduced not only dopamine potency but also its maximal responses, whereas in dopamine mediated GTPγS recruitment and cAMP production assays, 1H-indole-2-carboxamide showed only a reduction in dopamine potency . This indicates that this ligand is able to modulate dopamine binding to the orthosteric site of the receptor in such a way that not only it reduces dopamine potency but interestingly, depending on the functional assay, reduces dopamine efficacy. Furthermore, they confirmed that the residues valine 91 and glutamic acid 95 on the second extracellular loop of the D 2 receptor were crucial for maintaining the allosteric properties of both the leading compound SB269652
and the 1H-indole-2-carboxamide derivative.
The next step taken by Mistry et al. (2015) was to extend the carboxamide group of the 1H-indole-2-carboxamide moiety by adding a fragment derived from SB269652 that extended away from the indole-2-carboxamide moiety and included a tertiary amine group, N-((trans)-4-(2-(dimethylamino)ethyl)cyclohexyl)-1H-indole-2-carboxamide (compound 9a in Mistry et al., 2015) .
Interestingly, the modification did not alter the negative allosteric effect of the molecule in functional assays with dopamine; however, in spiperone radioligand-binding assays, the compound behaved as a competitive ligand. This suggests that the protrusion of the molecule into the orthosteric binding site is not sufficient to alter dopamine binding and action, but is sufficient to alter the binding of spiperone, which has a bulkier structure. Moreover, a further extension of the 1H-indole-2-carboxamide moiety transformed these analogues into pure competitive ligands.
Subsequently, Mistry et al. (2015) generated analogues from the 1H-indole-2-carboxamide moiety with bicyclic heteroaromatic ring at the carboxamide N-substituent of the molecule.
A key determinant of affinity for these analogues was the degree of N-substitution of the carboxamide moiety. In particular, the mono-substituted derivatives retained their activity while the di-substituted This article has not been copyedited and formatted. The final version may differ from this version. . Notably, the linear increased in the size of alkyl substituents (from N-ethyl to N-propyl and to N-butyl) improved both affinity and negative cooperativity, progressively. The N-butyl substituent (compound 11d in Mistry et al., 2015, Figure 2) was the compound with the most pronounced profile, which suggests that the alkyl substituents bind to an hydrophobic part of the receptor core. Consistent with this, polar substituents were not active. Figure 2) . It is worth noting that compound 36 is identical to compound 18b from the study by Shoneberg et al. (2015) , and, therefore, two independent approaches led to the same optimized compound.
One important aspect of the work of Mistry et al. (2015) that needs to be addressed concerned the allosteric mechanism through which SB269652 analogous operate across D 2 or D 3 receptor dimers. As previously discussed, the allosteric properties of SB269652 might lie in the ability to modify the affinity for orthosteric ligands across D 2 or D 3 receptor dimers. However, as discussed by Mistry et al. (2015) , the 1H-indole-2-carboxamide moiety and its derivatives do not require an allosterism across dimer types of interaction in order to function as allosteric modulators. In fact, these compounds do not
This article has not been copyedited and formatted. The final version may differ from this version. have an orthosteric pharmacophore, and are small enough to solely interact with the allosteric site of the receptor and, therefore, to exert allosteric effects within the same receptor protomer . Moreover, adding fragments of SB269652 and thus extending the carboxamide group away from the 1H-indole-2-carboxamide moiety, led to a critical extension: the synthesis of the peculiar compound 9a (see above), which remained allosteric only for dopamine but not for spiperone. These two distinctive behaviors of 9a for the two orthosteric ligands strongly suggest that the chemical extension was interfering with the binding of spiperone at the orthosteric site of the same promoter.
Otherwise, if 9a allosteric effects were exerted across dimers, the compound would have shown an allosteric effect for spiperone as well. Furthermore, there is evidence that support the concept that many allosteric modulators modify the binding properties of orthosteric ligands at the promoter level instead of across dimers. In particular, Kruse et al. (2013) crystallized the ternary complex structure formed by the allosteric modulator LY2119620 and the orthosteric agonist iperoxo which were simultaneously bound to the muscarinic M 2 receptor (Kruse et al., 2013) . The crystal structure showed that LY2119620 binds to a largely pre-formed binding site in the extracellular vestibule of the iperoxomuscarinic M 2 receptor complex and induces slight contraction of the outer binding pocket of the receptor that profoundly modifies the binding properties of the orthosteric site of the M 2 receptor.
Finally, it is worth noting that the indole-2-carboaxamide chemical structure of SB269652 is very similar to a recently identified positive allosteric modulator for D 2 and D 3 receptors, suggesting that understanding the binding mechanism of SB269652 to these receptors could lead to the development of both D 2 and D 3 receptor-specific positive and negative allosteric compounds (Wood et al., 2016) .
Dopamine receptor dimerization and allosteric effect of SB269652
Dopamine receptors are distributed in several areas of the brain and are pharmacologically targeted, in order to treat psychosis by decreasing their activity or Parkinson's disease by increasing their activity.
This article has not been copyedited and formatted. The final version may differ from this version. Like most GPCRs, they have been shown to behave like homodimers and heterodimers (Maggio et al., 2008 (Maggio et al., , 2015 . As previously explained, SB269652 and its derivatives exert their preeminent allosteric effect on dopamine receptors across dimers. Given that their allosteric effect is strictly dependent on the fraction of receptor dimers in respect to the fraction of monomers, in fact, these compounds would exert a negative modulatory effect only on receptors dimers, and a competitive antagonism only on receptor monomers. Regarding GPCR dimerization, mounting evidence indicates that it is a dynamic process, whereby receptors show a monomer-dimer equilibrium characterized by rapid association and dissociation processes (Scarselli et al., , 2016 . In a recent work, Tabor et al. (2016) receptor dimerization. In particular, they calculated that, at expression levels comparable to those detected in the caudate and putamen, in vivo (Boyson et al., 1986) , the percentage of dopamine D 2 receptor dimers compared to monomers was about 20%. Therefore, bitopic compounds would act as competitive antagonists on the 80% of the receptors and as allosteric modulators on the remaining 20%.
In comparison, if it is considered that in other parts of the brain, like the limbic system (ventral striatum) and the cortex, dopamine receptor levels are considerably lower (Hall et al., 1994) , and so the percentage of receptor dimers, the chances of an allosteric type of behavior for these bitopic compounds would dramatically decrease in comparison with the caudate/putamen. As also explained in the review of Conn et al. (2009) , one of the advantages of allosteric modulators with limited negative cooperativity, is that they would impose a 'ceiling' on the magnitude of their pharmacological effects.
In fact, this property would allow a high degree of titratability for these compounds, which could be administered at large doses with minor side effects if compared to large administered doses of orthosteric ligands.
This article has not been copyedited and formatted. The final version may differ from this version. Moreover, because it is commonly accepted that blocking D 2 receptor activity in the ventral striatum is responsible for the therapeutic antipsychotic effects and blocking the same receptors in the caudate/putamen is responsible for unwanted motor side effects (Jones and Pilowsky, 2002) ; drugs that are able to target these areas of the brain differently might lead to the development of novel pharmacological tools for the treatment of psychosis. We might then speculate that bitopic drugs acting as allosteric modulators across dimers may be able to discriminate between regions of the brain containing different percentages of dopamine receptor dimers. As a consequence, allosteric modulators in the caudate/putamen, setting a ceiling in the magnitude of their pharmacological effects for this area, could result in a reduction of their motor side effects and thus an increase in their tolerance.
Importantly, as demonstrated by Tabor et al. (2016) , agonists promote dopamine receptor dimer formation. Therefore, increases in dopamine levels would result in increases in the percentage of dopamine receptor dimers, which would make bitopic drugs with a negative modulatory effect across dimers, even safer.
Consistent with this concept, the [ 35 S]GTPγS recruitment data in Silvano's paper could be explained by the inability of 1 µM dopamine and the ability of 10 µM dopamine to generate enough dopamine receptor dimers on which SB269652 could direct its allosteric effects (Silvano et al., 2010) .
To this purpose, it is interesting to mention that the only in vivo data available with SB269625 were published in an abstract form long before the compound was recognized to be allosteric (Taylor et al., 1999) . SB269652 was shown to have no effect on the basal release of dopamine in the striatum and nucleus accumbens, but it prevented the inhibition of dopamine release induced by the D 2 /D 3 agonist quinelorane in the nucleus accumbens but not in the striatum. These data clearly indicate that the activity of SB269652 has a brain regional selectivity. This regional selectivity cannot be attributed, as originally it was assumed, to the preferential antagonism of this compound at D 3 receptor, as D 3
receptors have a marginal role in regulating dopamine release in respect to D 2 receptor (Joseph et al., This article has not been copyedited and formatted. The final version may differ from this version. 2002). Furthermore, SB269652 showed no effect on amphetamine-induced hyperactivity, and, in contrast to the orthosteric antagonist haloperidol, it did not induce catalepsy, suggesting that this compound may be devoid of side-effects normally associated with orthosteric dopamine receptor antagonists (Taylor et al., 1999) .
In contrast to bitopic compounds that exert their negative allosteric effect across dimers, allosteric compounds that exert negative modulatory effect on the monomer would not be influenced by receptor dimerization. In this case, differences in receptor concentration among areas of the brain should not influence their allosteric properties Even though pure allosteric modulators would behave in the same way, regardless of tissue-specific receptor dimerization, they would be good drugs anyway, because of the physiological ceiling effects imposed by their intrinsic nature.
Allosteric drugs as new antipsychotic agents
One of the main disadvantages in the use of first-generation antipsychotics is that when occupancy of the dopamine D 2 receptors in the caudate/putamen reaches 75-80%, extrapyramidal side effects start to appear. Nevertheless, this critical point of receptor occupancy of 60-80% should be reached in other area of the brain, such as the limbic system and the cortex, in order to obtain a therapeutic effect (Kasper et al., 1999; Remington and Kapur, 1999; Kapur et al., 2000) . As a consequence, clinicians have to titrate the dosage of antipsychotics directly on patients in order to stay in such a narrow therapeutic range of receptor occupancy, a "gamble" that often leads to poor adherence to antipsychotic prescriptions (Haddad et al., 2014) .
Unfortunately, even the second generation of antipsychotic drugs, which have additional effects on serotonin receptors (mostly 5HT 2A type) and therefore need a reduced D 2 dopamine receptor occupancy to be effective, were not extrapyramidal side effect-free (Rummel-Kluge et al., 2010) . In particular, the severity of extrapyramidal side effects varies in relation to the particular second-generation agent used
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(with clozapine having the lowest risk and risperidone the highest) and its dosage; the higher the dose, the more intense the extrapyramidal side effects are, which indicates that the safety of these second generation drugs depends on the level of receptor occupancy (Divac et al., 2014) .
The antipsychotic aripiprazole seems to have lower propensity for extrapyramidal side effects. Even at low doses, aripiprazole reaches receptor occupancy of 85% without inducing dystonia and parkinsonism, which are conversely observed for higher striatal occupancy (>90%) (Mamo et al., 2007) .
The lack of dystonia and Parkinsonism is attributed to its partial agonist properties that prevent complete receptor inactivation, but as described above, other mechanisms are probably responsible for it (Mailman and Murthy, 2010) . Nevertheless, akathisia is one of aripiprazole's most frequent and troublesome extrapyramidal side effects, being present in approximately 15-25% of patients with schizophrenia and bipolar mania taking the drug (Fleischhacker, 2005; Kinghorn and McEvoy, 2005; Poyurovsky, 2010) .
Given the arguments above, the need for new antipsychotic drugs showing minor or no extrapyramidal side effects is evident. Since targeting dopamine D 2 receptors still remains the main strategy to reduce psychotic symptoms, an alternative way to target these receptors could be the use of allosteric compounds. As discussed above, allosteric drugs with modest negative cooperativity have a ceiling effect that should allow physiological adaptation of dopamine neurotransmission to overcome their block and prevent the onset of extrapyramidal side effects.
Furthermore, the hypothetical higher dopamine receptor dimerization in caudate/putamen in respect to other areas of the brain should further improve the benefit/risk profile of compounds with bitopic properties that exert the allosteric effect only on receptor dimers. As a matter of fact, Wang et al.
(2010) found a significantly enhanced expression of dopamine D 2 receptor dimers and decreased expression of D 2 receptor monomers in the postmortem striatal tissue of schizophrenic patients (Wang et al., 2010) . Furthermore, they demonstrated that treatment of rats with amphetamine, a drug that This article has not been copyedited and formatted. The final version may differ from this version. increases dopamine concentration in the synaptic cleft, increased D 2 dopamine receptor dimerization in the striatum, while the antipsychotic haloperidol did not alter D 2 dimer levels (Wang et al., 2010) .
These data are in good agreement with the study in vitro of Tabor et al. (2016) and they support the concept that bitopic drugs with allosteric effect across dimers could have a profound impact on the development of novel and more safe antipsychotic therapies.
Until now, SB269652 remains unique in its mechanism of action, as no other bitopic ligands have been reported to have an allosteric effect across dimers. Nevertheless, allostery across dimers has been reported for ligands that bind to the orthosteric site of GPCRs homo-and heteromers (Smith and Milligan, 2010) . Recently, Bonaventura et al. (2015) 
Concluding remarks
This article has not been copyedited and formatted. The final version may differ from this version. The last ten years have witnessed an explosion in the amount of work done on allosteric modulation of GPCRs. Muscarinic (Jakubík and El-Fakahany, 2010) , glutamate (Lundström et al., 2016) and adenosine (Romagnoli et al., 2015) are only some of the receptors that have been widely explored to find allosteric drugs. At the moment, only two allosteric compounds for GPCRs have been approved for marketing, cinacalet, a positive allosteric modulator of the calcium sensing receptor which is used in hyperparathyroidism, and maraviroc, a negative allosteric modulator of chemokine receptor 5 that is used in the treatment of HIV infections. The experience in using these drugs is still somewhat limited; nevertheless they are a proof of concept that allosteric compounds for GPCRs can be used as therapeutic agents in clinic.
Schizophrenia is a chronic disease and the treatment with the currently available drugs is often troublesome because of the difficulty obtaining a good therapeutic effect without serious collateral side effects. For these reasons, allosteric drugs are good candidates to overcome these problems, at least in part. Indeed, SB269652 is the first negative allosteric modulator of dopamine D 2 and D 3 receptors, and the search for optimized analogues has led to more potent bitopic modulators and pure allosteric drugs.
While it is difficult to predict whether allosteric drugs at dopamine receptors will have the same efficacy of the classic orthosteric drugs, their therapeutic potential stands on a solid preclinical background, and it is worth the effort to design optimized derivatives of SB269652 to explore their efficacy in clinic.
In conclusion, compared to the orthosteric-targeted ligands, allosteric molecules show increased specificity for particular GPCR subunits and reduced side effects. Although difficult to develop, allosteric modulators represent one of the most valuable pharmaceutical tools for the development of potent and more selective therapeutic strategies for the treatment of a variety of pathologies.
This article has not been copyedited and formatted. The final version may differ from this version. Schematic representation of the allosteric binding mode of SB269652 to dopamine receptor dimer and monomer. SB269652 is represented with its three main parts, the 7CN-THIQ group (pink), the transcyclohexylene spacer in the middle and the indole-2-carboxamide tail (sky blue). In the left part of the image, SB269652 is shown binding in a bitopic mode to one protomer of the dopamine dimer, the 7CN-THIQ group to the orthosteric site (Orth) and the indole-2-carboxamide group to the allosteric site (All1), and exerting an allosteric effect across dimer on dopamine sitting on the orthosteric site of the other protomer (Lane et al., 2014) . In the right part of the image, SB269652 is shown binding to a dopamine occupied monomer and preventing the dissociation of dopamine from the same receptor. In this configuration, the indole-2-carboxamide group would bind to the allosteric site as shown for SB269652 in the bitopic pose (All1), while the 7CN-THIQ group would engage an additional site on the extracellular part of the receptor (All2). This second arrangement of SB269652 on the dopamineoccupied receptor would be unfavorable respect to the bitopic binding mode, and it would occur only for high doses of the drug.
Figure 2
Chemical structure of optimized SB269652 analogues. Value of K B (functional affinity) and αβ (allosteric cooperativity with dopamine) were taken from Shonberg et al. (2015) and Mistry et al. (2015) . The part of the molecule boxed in pink binds to the orthosteric site while the part boxed in light blue binds to the allosteric site. For comparison we added a compound (25d) lacking an allosteric effect.
